06.09.25 -- To Enhance Biotech Investments, Involve CDMOs Early In CMC Decisions

Discover how developability assessments can streamline lead candidate selection in this Abzena webinar. Learn how evaluating key attributes like manufacturability, safety, and efficacy early in drug development helps reduce risks and improve clinical success rates. Explore advanced methodologies and technologies that provide comprehensive insights, enabling better decision-making and more efficient progress toward regulatory approval. Click here to learn more.

Because clinical applications for AAV are increasing rapidly, there is a high demand for further increasing yields as well as product quality, particularly for a higher percentage of full capsids in the final product.

Executing or skipping an engineering run is a consequential decision for any biopharma or CDMO and should be supported by all available data as well as a thorough risk assessment.

Stay up to date on the future of CDMOs by reading about key trends, such as adopting a customer-centric mindset, agile manufacturing, and embracing digitalization.

Chief Editor Louis Garguilo provides a brief introduction and background to our Outsourced Pharma Live Event: CMC Compliance Through CDMO Collaborations.

Analytical method development is a critical phase in development, and its successful implementation is essential for delivering high-quality products to market efficiently and effectively.

Discover how implementing a strategic approach to optimize the platform can establish a solid foundation for the efficient, reliable, and successful manufacturing of biopharmaceutical products.

This research demonstrates the potential of high-pressure sterile filtration to enhance efficiency, reduce waste, and accelerate the development of innovative therapies.

Learn how the advanced principles of process intensification can be applied to process and equipment design, increasing facility throughput, and ultimately offering a wide range of benefits to customers.

In this presentation, industry-leading bioprocess experts explore the challenges and opportunities that arise when implementing Quality by Design (QbD) in biologics development and manufacturing.

Join KBI Biopharma for a webinar on transposase-enabled cell line development. Built on Selexis® SUREtechnology™ and CHO-M™, this platform delivers high titers, rapid development, and stability for complex biologics. Learn how it accelerates timelines, supports diverse molecule formats, and meets regulatory demands—offering a scalable, efficient alternative to traditional CLD methods. Perfect for teams seeking speed, quality, and flexibility in biotherapeutic development. Click here to learn more.

See how Corvus, a small biotech, was able to advance Mupadolimab from development to clinical trials, leveraging flexible capacity, proven antibody platforms, and regulatory-ready CMC support.

ArQ®-Vita enables reliable, large-volume intramuscular delivery in a compact, patient-friendly device — ideal for chronic condition treatments.

Review how our state-of-the-art instrumentation, technology, and scientific expertise are capable of supporting all aspects of biologics testing across all modalities.

Take a look at our full range of support services to streamline manufacturing processes through to the commercialization of aseptic and lyophilized products.

BD Neopak Glass Pre-fillable Syringe is built on years of BD’s unmatched experience partnering with leading biopharmaceutical companies to support drug development and launch.